Williams: Zosano Pharma (ZSAN) is worth a look…
Jeff Williams of PennyPro.com says that Zosano Pharma Corp. (ZSAN) is a play right now thanks to an interesting…
Read MorePopular Categories:
Jeff Williams of PennyPro.com says that Zosano Pharma Corp. (ZSAN) is a play right now thanks to an interesting…
Read MoreKyle Dennis of BiotechBreakouts.com says that Summit Therapeutics (SMMT) is worth looking at now ahead of a Phase 2…
Read MoreKyle Dennis of BiotechBreakouts.com says that Exelixis Inc. (EXEL) is poised to move thanks to late-stage approvals for two different…
Read MoreThe backstory: Axovant Sciences Ltd. (AXON) was a company I was avoiding last summer, but that I am looking at…
Read MoreThe back story: Marinus Pharmaceuticals (MRNS) saw a positive data release in mid-September, which caused the tock to pop from…
Read MoreKyle Dennis of BiotechBreakouts.com like Synergy Pharmaceuticals Inc. (SGYP) based on a drug for irritable-bowl syndrome that he thinks has…
Read MoreKyle Dennis of BiotechBreakouts.com revisited Bellicum Pharmaceuticals (BLCM) on the Raging Bull podcast, because the company has early Phase 1-2…
Read MoreThe backstory: Marijuana legalization is becoming a thing. With a bunch of states legalizing cannabis for medicinal use, and a few…
Read MoreKyle Dennis of BiotechBreakouts.com looked back at Oncosec Medical (ONCS) and Melinta Therapeutics (MLNT) in the Raging Bull podcast, noting…
Read MoreWhen it comes to technical analysis, I believe that simple tends to be better. That’s why I typically use channel…
Read MoreKyle Dennis of BiotechBreakouts.com said that Axovant Sciences (AXON) has three Alzheimer’s drug test-data releases coming in January, which is…
Read MoreThe set-up: It’s hard to find a sector that isn’t stretched to the moon and giving good trade scenarios right…
Read MoreWith biotechnology having been hammered in the market over the last few weeks, Jeff Bishop of TopStockPicks.com thinks it’s about…
Read MoreThe setup: Catalyst Pharmaceuticals (CPRX) has been forecasting a fourth-quarter Phase 3 data release for its drug Firdapse in treatment…
Read MoreThe back story: Eiger BioPharmaceuticals Inc. (EIGR) has caught my eye again. In August, I saw a nice opportunity for…
Read More